Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic study of TS-172 in healthy adult males
jRCT2071250044Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Primary endpoints: Urinary phosphorus excretion and Urinary sodium excretion. Started Aug 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on jRCT2071250044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250044.